Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.52 |
| ▸ | GRM5 | P41594 | 8/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320016 | 0.91 | CNR1 (0.54) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL31223106 | 0.87 | PDK4 (0.53) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL24670855 | 0.87 | PDK4 (0.53) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL19701841 | 0.86 | CNR1 (0.55) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL19701842 | 0.86 | PDK4 (0.53) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL4888709 | 0.86 | CNR1 (0.53) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL15556190 | 0.85 | CNR1 (0.55) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL31342210 | 0.85 | CNR1 (0.55) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL23721775 | 0.85 | PDK4 (0.52) | CNR1PDK4GRM1GRM5HTR6 | |
| SCHEMBL23240953 | 0.84 | CNR1 (0.55) | CNR1PDK4GRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2004604-B1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009015867-A1 | SUBSTITUTED ARYL OR HETEROARYLPIPERDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| EP-2020405-A1 | Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-02-04 | — | — | EP | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-1842846-A1 | Phenylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| EP-1487811-B1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007096186-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| EP-1826201-A1 | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1487811-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003080586-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CNR1 4030/4885PDK4 1750/4885GRM1 3275/4885 |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, BAD | CNR1 4030/4885PDK4 1750/4885GRM1 3275/4885 |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, AIFM1 | CNR1 3516/4885PDK4 1745/4885GRM1 2636/4885 |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | CNR1 238/4885PDK4 156/4885GRM1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.